2seventy Bio, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
2seventy bio announced its Q1 2025 results, highlighting a net income of $0.5 million and progress on its merger agreement with Bristol-Myers Squibb.
2seventy bio's Q3 2024 results reflect a strategic shift towards Abecma commercialization, following the sale of its oncology and autoimmune programs to Regeneron and its megaTAL program to Novo Nordisk.
2seventy bio reports a net income of $24.9 million for Q2 2024, driven by strategic asset sales and a focus on Abecma commercialization.
2seventy bio reports a net loss of $52.7 million for Q1 2024 and completes a strategic realignment focusing on Abecma commercialization.